Top Buy Stocks
Sign In
NASDAQ:CTMX
CytomX Therapeutics Stock Earnings Reports
$2.03
+0.0300 (+1.50%)
At Close: May 16, 2025
CytomX Therapeutics Earnings Calls
Q1 2025
Beat
$0.270 (50.00%)
| Release date | May 12, 2025 |
| EPS estimate | $0.180 |
| EPS actual | $0.270 |
| EPS Surprise | 50.00% |
| Revenue estimate | 4M |
| Revenue actual | 50.917M |
| Revenue Surprise | 1,172.93% |
Q4 2024
Beat
$0.220 (195.65%)
| Release date | Mar 06, 2025 |
| EPS estimate | -$0.230 |
| EPS actual | $0.220 |
| EPS Surprise | 195.65% |
| Revenue estimate | 13.04M |
| Revenue actual | 38.093M |
| Revenue Surprise | 192.12% |
Q3 2024
Beat
$0.0700 (141.18%)
| Release date | Nov 07, 2024 |
| EPS estimate | -$0.170 |
| EPS actual | $0.0700 |
| EPS Surprise | 141.18% |
| Revenue estimate | 13.533M |
| Revenue actual | 33.432M |
| Revenue Surprise | 147.03% |
Q2 2024
Missed
-$0.0800 (-14.29%)
| Release date | Aug 08, 2024 |
| EPS estimate | -$0.0700 |
| EPS actual | -$0.0800 |
| EPS Surprise | -14.29% |
| Revenue estimate | 19.99M |
| Revenue actual | 25.115M |
| Revenue Surprise | 25.64% |
Last 4 Quarters for CytomX Therapeutics
Below you can see how CTMX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
Q2 2024
Missed
| Release date | Aug 08, 2024 |
| Fiscal end date | Jun 30, 2024 |
| Price on release | $1.18 |
| EPS estimate | -$0.0700 |
| EPS actual | -$0.0800 |
| EPS surprise | -14.29% |
| Date | Price |
|---|---|
| Aug 02, 2024 | $1.31 |
| Aug 05, 2024 | $1.26 |
| Aug 06, 2024 | $1.26 |
| Aug 07, 2024 | $1.16 |
| Aug 08, 2024 | $1.18 |
| Aug 09, 2024 | $1.20 |
| Aug 12, 2024 | $1.19 |
| Aug 13, 2024 | $1.16 |
| Aug 14, 2024 | $1.16 |
| 4 days before | -9.92% |
| 4 days after | -1.69% |
| On release day | 1.69% |
| Change in period | -11.45% |
Q3 2024
Beat
| Release date | Nov 07, 2024 |
| Fiscal end date | Sep 30, 2024 |
| Price on release | $1.00 |
| EPS estimate | -$0.170 |
| EPS actual | $0.0700 |
| EPS surprise | 141.18% |
| Date | Price |
|---|---|
| Nov 01, 2024 | $1.05 |
| Nov 04, 2024 | $1.01 |
| Nov 05, 2024 | $0.99 |
| Nov 06, 2024 | $1.00 |
| Nov 07, 2024 | $1.00 |
| Nov 08, 2024 | $1.09 |
| Nov 11, 2024 | $1.04 |
| Nov 12, 2024 | $1.04 |
| Nov 13, 2024 | $1.01 |
| 4 days before | -4.76% |
| 4 days after | 1.00% |
| On release day | 9.00% |
| Change in period | -3.81% |
Q4 2024
Beat
| Release date | Mar 06, 2025 |
| Fiscal end date | Dec 31, 2024 |
| Price on release | $0.617 |
| EPS estimate | -$0.230 |
| EPS actual | $0.220 |
| EPS surprise | 195.65% |
| Date | Price |
|---|---|
| Feb 28, 2025 | $0.677 |
| Mar 03, 2025 | $0.650 |
| Mar 04, 2025 | $0.653 |
| Mar 05, 2025 | $0.615 |
| Mar 06, 2025 | $0.617 |
| Mar 07, 2025 | $0.665 |
| Mar 10, 2025 | $0.670 |
| Mar 11, 2025 | $0.620 |
| Mar 12, 2025 | $0.599 |
| 4 days before | -8.85% |
| 4 days after | -3.00% |
| On release day | 7.71% |
| Change in period | -11.58% |
Q1 2025
Beat
| Release date | May 12, 2025 |
| Fiscal end date | Mar 31, 2025 |
| Price on release | $2.13 |
| EPS estimate | $0.180 |
| EPS actual | $0.270 |
| EPS surprise | 50.00% |
| Date | Price |
|---|---|
| May 06, 2025 | $0.97 |
| May 07, 2025 | $0.96 |
| May 08, 2025 | $1.09 |
| May 09, 2025 | $0.93 |
| May 12, 2025 | $2.13 |
| May 13, 2025 | $2.50 |
| May 14, 2025 | $2.38 |
| May 15, 2025 | $2.00 |
| May 16, 2025 | $2.03 |
| 4 days before | 120.41% |
| 4 days after | -4.69% |
| On release day | 17.37% |
| Change in period | 110.06% |
CytomX Therapeutics Earnings History
Earnings Calendar
FAQ
When is the earnings report for CTMX?
CytomX Therapeutics (CTMX) has scheduled its earnings report for Aug 14, 2025 after the markets close.
What is the CTMX price-to-earnings (P/E) ratio?
CTMX P/E ratio as of May 16, 2025 (TTM) is 4.98.
What is the CTMX EPS forecast?
The forecasted EPS (Earnings Per Share) for CytomX Therapeutics (CTMX) for the first fiscal quarter 2025 is $0.0600.
What are CytomX Therapeutics's retained earnings?
On its balance sheet, CytomX Therapeutics reported retained earnings of $50.92 million for the latest quarter ending Mar 31, 2025.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports?
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
